Aprepitant Capsules and Darolutamide
Determining the interaction of Aprepitant Capsules and Darolutamide and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of darolutamide, which is a substrate of both the isoenzyme and the efflux transporter. When darolutamide was coadministered with itraconazole, a dual P-gp and potent CYP450 3A4 inhibitor, mean darolutamide peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 40% and 70%, respectively, compared to administration of darolutamide alone. The interaction has not been studied with less potent inhibitors or lone inhibitors of CYP450 3A4 or P-gp. MANAGEMENT: Caution is advised when darolutamide is used with CYP450 3A4 or P-gp inhibitors. Patients should be monitored more frequently for adverse effects such as fatigue, hypertension, neutropenia and abnormal liver function tests, and the darolutamide dosage adjusted as necessary in accordance with the product labeling. References "Product Information. Nubeqa (darolutamide)." Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
Professional:MONITOR: Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of darolutamide, which is a substrate of both the isoenzyme and the efflux transporter. When darolutamide was coadministered with itraconazole, a dual P-gp and potent CYP450 3A4 inhibitor, mean darolutamide peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 40% and 70%, respectively, compared to administration of darolutamide alone. The interaction has not been studied with less potent inhibitors or lone inhibitors of CYP450 3A4 or P-gp.
MANAGEMENT: Caution is advised when darolutamide is used with CYP450 3A4 or P-gp inhibitors. Patients should be monitored more frequently for adverse effects such as fatigue, hypertension, neutropenia and abnormal liver function tests, and the darolutamide dosage adjusted as necessary in accordance with the product labeling.
- "Product Information. Nubeqa (darolutamide)." Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
Generic Name: aprepitant
Brand name: Cinvanti, Emend, Emend 3-Day, Emend 2-Day
Synonyms: Aprepitant
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Aprepitant Capsules-Darpaz
- Aprepitant Capsules-Darunavir
- Aprepitant Capsules-Darunavir and Cobicistat
- Aprepitant Capsules-Darunavir Oral Suspension
- Aprepitant Capsules-Darunavir Tablets
- Aprepitant Capsules-Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide
- Darolutamide-Aprepitant Injection
- Darolutamide-Aprepitant Intravenous
- Darolutamide-Aprepitant Oral Suspension
- Darolutamide-Aprepitant/Fosaprepitant Dimeglumine
- Darolutamide-Apresazide
- Darolutamide-Apresoline